CNS Pharmaceuticals, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- CNS Pharmaceuticals, Inc. stock issued during period, value, new issues for the quarter ending 2026-03-31 was $482.00K, a 94.66% decline year-over-year.
- CNS Pharmaceuticals, Inc. stock issued during period, value, new issues for the quarter ending 2025-06-30 was $4.50M, a 85.82% increase year-over-year.
- CNS Pharmaceuticals, Inc. stock issued during period, value, new issues for the quarter ending 2025-03-31 was $9.03M, a 171.18% increase year-over-year.
- CNS Pharmaceuticals, Inc. stock issued during period, value, new issues for the quarter ending 2024-09-30 was $12.38M, a 9221.57% increase year-over-year.
- CNS Pharmaceuticals, Inc. stock issued during period, value, new issues for fiscal 2023 was $2.32M, a 85.55% decline from fiscal 2022.
- CNS Pharmaceuticals, Inc. stock issued during period, value, new issues for fiscal 2022 was $16.04M, a 244.62% increase from fiscal 2021.
- CNS Pharmaceuticals, Inc. stock issued during period, value, new issues for fiscal 2021 was $4.65M.
- CNS Pharmaceuticals, Inc. stock issued during period, value, new issues for fiscal 2019 was $10.29M, a 2536.30% increase from fiscal 2018.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-03-31 | $482.00K 10-Q · filed 2026-08-12 | |
| 2025-06-30 | $4.50M 10-Q · filed 2026-08-12 | |
| 2025-03-31 | $9.03M 10-Q · filed 2026-08-12 | |
| 2024-09-30 | $12.38M 10-Q · filed 2025-11-14 | |
| 2024-06-30 | $2.42M 10-Q · filed 2025-11-14 | |
| 2024-03-31 | $3.33M 10-Q · filed 2025-11-14 | |
| 2023-12-31 | $2.32M 10-K · filed 2025-03-31 | |
| 2023-09-30 | $132.85K 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $1.97M 10-Q · filed 2024-11-14 | |
| 2022-12-31 | $16.04M 10-K · filed 2024-04-01 | |
| 2022-03-31 | $10.63M 10-Q · filed 2023-11-14 | |
| 2021-12-31 | $4.65M 10-K · filed 2023-03-31 | |
| 2021-03-31 | $144.84K 10-Q · filed 2022-11-10 | |
| 2019-12-31 | $10.29M 10-K · filed 2021-02-12 | |
| 2019-09-30 | $100.00K 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $1.41M 10-Q · filed 2020-11-12 | |
| 2018-12-31 | $390.50K 10-K · filed 2020-03-12 | |
| 2018-03-31 | $390.50K 10-Q · filed 2019-12-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |